Beyond borders 2016: Biotech financing

whitePaper | April 14, 2022

In the nearly 50 years since the first genetic engineering experiments, the United States has become the world’s biotechnology powerhouse,

whitePaper | September 1, 2021

This report advocates for increased, long-term public investment in research and innovation, particularly in the life sciences sector, to accelerate the UK on its trajectory as a global leader in the field. This report sets out recommendations ahead of the Comprehensive Spending Review for policymakers to support innovative businesses, achieve the Prime Minister’s aim of becoming a life sciences superpower, and ultimately, deliver health benefits for Britain – and the world – for generations to come.

whitePaper | January 20, 2023

We provide an overview of the human microbiome market, the observed challenges, how to overcome them and introduce future opportunities for pharmaceutical.

whitePaper | August 25, 2022

Patient engagement has become a measure of healthcare analytics that many in rehab therapy have sought to quantify.

whitePaper | December 13, 2022

Define the ongoing pandemic of antimicrobial resistance. Discuss how we can address the ongoing pandemicin the Clinical Microbiology Laboratory

whitePaper | May 24, 2023

The Greater Zurich Area Ltd (GZA), Apellis, and Korn Ferry co-hosted a virtual roundtable for a select group of biopharma leaders interested in expanding their operations into Europe. The panel brought together European launch specialists, talent experts, and Swiss government officials to cover critical questions and guiding principles necessary for a successful European launch, as well as insider knowledge of how to best navigate the regulatory environment.